CN110638842A - 一种改善高血糖的益生菌组合物 - Google Patents
一种改善高血糖的益生菌组合物 Download PDFInfo
- Publication number
- CN110638842A CN110638842A CN201810667223.1A CN201810667223A CN110638842A CN 110638842 A CN110638842 A CN 110638842A CN 201810667223 A CN201810667223 A CN 201810667223A CN 110638842 A CN110638842 A CN 110638842A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- hyperglycemia
- probiotics
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 35
- 239000008280 blood Substances 0.000 claims abstract description 35
- 230000000529 probiotic effect Effects 0.000 claims abstract description 26
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 8
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 8
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 8
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 8
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 8
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 8
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract 3
- 239000000654 additive Substances 0.000 claims abstract 2
- 239000008103 glucose Substances 0.000 claims description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 238000009655 industrial fermentation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 206010056997 Impaired fasting glucose Diseases 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- 241000702460 Akkermansia Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种改善高血糖的益生菌组合物，该益生菌组合物由益生菌和食品或医学上可接受的辅料或添加剂组成，其特征在于，所述的益生菌由以下重量份的益生菌组成：短双歧杆菌20‑25份，长双歧杆菌20‑25份，干酪乳杆菌15‑20份，嗜酸乳杆菌15‑20份，植物乳杆菌5‑10份，鼠李糖乳杆菌5‑10份，青春双歧杆菌5份。本发明所述的益生菌组合物具有降低血糖的作用。
Description
技术领域
本发明涉及生物医药领域，涉及一种改善高血糖的益生菌组合物，以指定的若干种益生菌为原料组合而成。
背景技术
人体在进食过程中摄入碳水化合物，经消化系统消化为葡萄糖并吸收入血，此时血糖升高，胰岛素开始分泌，葡萄糖进入肝脏或肌肉合成成为糖原，血糖逐渐下降；在人体血糖低于阈值时，胰高血糖素开始分泌，糖原重新分解为葡萄糖进入血液，提供能量。因此，人体的血糖处在一个相对稳定的变动范围之内。
高血糖是一种代谢类疾病，指的是血糖超过正常值，身体胰岛素分泌绝对量不足（I型糖尿病）、或身体靶器官对胰岛素不敏感造成相对不足（II型糖尿病），导致血糖无法快速合成糖原而滞留在血液中，造成血糖升高。除非特别说明，本文所指的糖尿病均为II型糖尿病。另外，长期高血糖同时会造成糖化血红蛋白升高，临床上也经常以此指标来参考评价糖尿病状况。
严重的高血糖称为糖尿病，是一种通常不可逆的糖代谢紊乱疾病。因病人血糖过高，肾脏中的肾小管重吸收达到极限，血糖无法被完全回收而导致尿糖。按照美国糖尿病协会的标准，正常人体空腹（8小时以上）血糖应小于5.6mmol/l，餐后2小时血糖应小于11mmol/l。符合以下条件之一被定义为糖尿病：1）空腹血糖大于等于6.9 mmol/l；2）餐后2小时血糖大于等于11 mmol/l。
临界型高血糖又称为初发型糖尿病，指的是身体糖代谢出现初步紊乱的病理状态。分为以下三种类型：①空腹血糖受损（Impaired fasting glucose，IFG）：空腹血糖大于等于5.6mmol/l，但小于6.9 mmol/l；②餐后血糖受损（Impaired Glucose Tolerance，IGT）：空腹状态下一次性饮用75g葡萄糖，2小时后血糖大于等于7.8mmol/l，但小于11mmol/l；③混合型：同时兼有IFG和IGT。
糖尿病是对身体健康的严重威胁，长期的高血糖和反复的血糖剧烈波动会损伤内脏和神经，尤其是末梢神经和末梢血管。常见的糖尿病并发症包括有：1、失明：因糖尿病导致的失明是我国失明人群的最主要诱因，导致视网膜血管发生黄斑病变，视力逐步丧失直至失明；2、截肢：糖尿病会造成末梢神经坏死，肌肉组织逐渐萎缩溃烂，直至截肢。糖尿病人常见腿部和足部受外伤而自身未发现，往往在造成严重溃烂后才意识到，正是因为其下肢神经坏死；3、肾病：糖尿病导致肾脏血管坏死，往往造成严重肾病；4、猝死：糖尿病人在通常状态下表现为高血糖，但往往由于尿糖、糖原储备过低而造成血糖急剧下降形成严重低血糖，身体转为代谢脂肪并生成大量酮体。过多的酮体在血液中积累会造成酮中毒，严重时若抢救不及时可导致死亡。
目前临床治疗糖尿病通常首先使用口服药物，包括二甲双胍、阿卡波糖等，增加机体对胰岛素的敏感性；但同一药物使用一段时间后身体往往会出现耐药性，此时更换药物，或口服的药物同时联合注射胰岛素可重新控制血糖，但可更换的药物有限，病人往往最终落入只能依赖胰岛素的境地。而对于临界高血糖（初发型糖尿病）人群，临床上目前并无可行的解决方案。
最近的科学研究发现，肠道菌群与血糖代谢有着密切联系。例如肠道中一种被称为Akkermansia Muciniphila的细菌在血糖控制中发挥着重要作用。其能够合成一种膜蛋白，该蛋白能够通过人体的Irgm-1受体与IFN-gamma相互作用，使得后者表达量下降，从而降低免疫系统对糖代谢的负面影响，进而改善糖尿病。通过饲喂的方式人为增加小鼠肠道中的Akkermansia Muciniphila细菌，可明显改善其因饮食造成的糖尿病，降低其空腹血糖和餐后血糖。与此同时，肠道中一类分泌丁酸盐的细菌被发现能够增加机体对胰岛素的敏感性、增强口服糖尿病药物的治疗效果。在临床实验中，给予糖尿病患者口服阿卡波糖的同时，口服特定益生元以增加肠道中分泌丁酸盐细菌的含量，能够有效增强药物疗效、更快的降低血糖和糖化血红蛋白。
益生菌是指对人体和动物肠道有益的细菌，可在肠道中定植，通过改善肠道环境来减少肠道中有害细菌的含量，并分泌一些对人体有益的物质。选用特定菌株、并采用特殊配比的益生菌能够调整肠道菌群向指定方向变化，增加肠道中特定细菌的含量。因此，通过服用益生菌来调整肠道菌群从而改善高血糖成为一种可能的方案。
发明内容
本发明目的在于，提供一种改善高血糖的益生菌组合物，包括：短双歧杆菌，长双歧杆菌，干酪乳杆菌，嗜酸乳杆菌，植物乳杆菌，鼠李糖乳杆菌、青春双歧杆菌。
在一个优选例中，所述的益生菌重量份分别为：短双歧杆菌20-25份，长双歧杆菌20-25份，干酪乳杆菌15-20份，嗜酸乳杆菌15-20份，植物乳杆菌5-10份，鼠李糖乳杆菌5-10份，青春双歧杆菌5份。
在一个优选例中，所述的益生菌重量份分别为：短双歧杆菌22份，长双歧杆菌22份，干酪乳杆菌18份，嗜酸乳杆菌18份，植物乳杆菌8份，鼠李糖乳杆菌7份，青春双歧杆菌5份。
在另一优选例中，所述的益生菌组合物还包括益生元成份。
在另一优选例中，所述的益生元包括低聚果糖，菊粉，低聚木糖，低聚异麦芽糖，低聚半乳糖等，优选为低聚果糖。
本发明的另一目的在于，提供一种降低血糖的方法，包括：给予对象服用上述的益生菌组合物。
在一个优选例中，所述对象空腹血糖大于等于5.6mmol/l但小于6.9 mmol/l，或餐后2小时血糖大于等于7.8mmol/l但小于11 mmol/l。
在一个优选例中，所述对象空腹血糖大于等于6.9 mmol/l，或餐后2小时血糖大于等于11 mmol/l。
在一个优选例中，所述的组合物每份含有50亿以上的活菌数量（CFU），较佳的100亿以上，更佳的200亿以上，更佳的300亿以上，更佳的500亿以上，更佳的1000亿以上。
在一个优选例中，所述对象每日服用一次所述的组合物。
在另一优选例中，所述对象每日服用二次所述的组合物。
本发明的其它方面由于本文的公开内容，对本领域的技术人员而言是显而易见的。
附图说明
图1、小鼠饮食诱导糖尿病过程中服用益生菌组合物的血糖对比图；图2、初发型糖尿病志愿者服用益生菌组合物后血糖前后对比图；图3、初发型糖尿病志愿者服用益生菌组合物后血糖降幅百分比。
具体实施方式
本发明人经过广泛的研究，找到一种改善高血糖的益生菌组合物。本发明可极好的应用于改善高血糖，极具效果优势。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。除非另外说明，否则百分比和份数按重量计算。
实施例1、预防高糖高脂饮食诱导的小鼠高血糖：
6周龄雄性C57/B6小鼠分为两组，每组10只，分为对照组和益生菌组，饲养于上海市实验动物中心。小鼠统一喂食脂肪含量为60%的高脂饲料，饮用水为添加了5%葡萄糖和5%果糖、共计10%糖份的饮用水，连续喂食8周。
将益生菌按照如下比例进行混合：短双歧杆菌22份，长双歧杆菌22份，干酪乳杆菌18份，嗜酸乳杆菌18份，植物乳杆菌8份，鼠李糖乳杆菌7份，青春双歧杆菌5份。每份益生菌组合物含有总数为50亿活菌，辅料为麦芽糊精，重量为0.2g，用0.5ml生理盐水溶解后灌胃。在上述喂食高糖高脂饮食的8周期间，每日进行两次灌胃饲喂益生菌溶液。低脂组和高脂对照组灌注0.2g麦芽糊精，同样用0.5ml生理盐水溶解。
测定小鼠实验前、实验后的空腹血糖，结果如图1所示。
实施例2、改善初发型糖尿病/临界高血糖：
选取成年男性女性各5名，进行空腹血糖测定，于上海市长征医院进行。随后每日口服2次益生菌组合物，益生菌比例按重量份计如下：
短双歧杆菌22份，长双歧杆菌22份，干酪乳杆菌18份，嗜酸乳杆菌18份，植物乳杆菌8份，鼠李糖乳杆菌7份，青春双歧杆菌5份。每份益生菌组合物含有总数为150亿活菌，辅料为麦芽糊精，额外添加低聚果糖、水果粉及木糖醇，重量为1.5g。用温水溶解后饮用，一日两次。
4周后，再次在上海市长征医院进行空腹血糖测定。结果如图2所示。可以看到，志愿者整体空腹血糖有明显下降，平均下降百分比如图3所示。
Claims (10)
1.一种改善高血糖的益生菌组合物，该组合物由益生菌和食品或医学上可接受的辅料或添加剂组成，其特征在于，所述的益生菌由以下重量份的益生菌组成：短双歧杆菌20-25份，长双歧杆菌20-25份，干酪乳杆菌15-20份，嗜酸乳杆菌15-20份，植物乳杆菌5-10份，鼠李糖乳杆菌5-10份，青春双歧杆菌5份。
2.如权利要求1所述的一种改善高血糖的益生菌组合物，其特征在于，所述的益生菌由以下重量份的益生菌组成：短双歧杆菌22份，长双歧杆菌22份，干酪乳杆菌18份，嗜酸乳杆菌18份，植物乳杆菌8份，鼠李糖乳杆菌7份，青春双歧杆菌5份。
3.如权利要求1或2所述的一种改善高血糖的益生菌组合物，其特征在于，除所述的益生菌外，所述的组合物还包括益生元成份，并且所述的益生元成份包括但不限于：低聚果糖，菊粉，低聚木糖，低聚异麦芽糖，低聚半乳糖。
4.如权利要求1-3所述的一种改善高血糖的益生菌组合物，其特征在于，所述的高血糖包含下列至少一种情况：空腹血糖大于等于5.6mmol/l；餐后2小时血糖大于等于7.8mmol/l。
5.如权利要求1-4所述的一种改善高血糖的益生菌组合物，其特征在于，所述的组合物类型为食品、保健食品或药品。
6.如权利要求1-4所述的一种改善高血糖的益生菌组合物，其特征在于，所述的组合物为粉剂、颗粒剂、片剂、液体制剂或胶囊。
7.如权利要求1-4所述的一种改善高血糖的益生菌组合物，其特征在于，所述的益生菌由工业发酵方法各自单独发酵制备而成，并且所述的混合物是由经混合而成。
8.一种降低血糖的方法，其特征在于，给予指定对象服用权利要求1-4所述的组合物。
9.如权利要求8所述的方法，其特征在于，所述对象空腹血糖大于等于5.6mmol/l但小于6.9 mmol/l，或餐后2小时血糖大于等于7.8mmol/l但小于11 mmol/l。
10.如权利要求8所述的方法，其特征在于，所述对象空腹血糖大于等于6.9 mmol/l，或餐后2小时血糖大于等于11 mmol/l。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810667223.1A CN110638842A (zh) | 2018-06-26 | 2018-06-26 | 一种改善高血糖的益生菌组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810667223.1A CN110638842A (zh) | 2018-06-26 | 2018-06-26 | 一种改善高血糖的益生菌组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110638842A true CN110638842A (zh) | 2020-01-03 |
Family
ID=68989032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810667223.1A Pending CN110638842A (zh) | 2018-06-26 | 2018-06-26 | 一种改善高血糖的益生菌组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110638842A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402464A (zh) * | 2020-12-14 | 2021-02-26 | 山东第一医科大学附属内分泌与代谢病医院 | 一种有益于2型糖尿病患者的复合益生菌组合物 |
| CN115137757A (zh) * | 2022-07-29 | 2022-10-04 | 承葛健康科技(广东)有限公司 | 一种辅助降血糖的益生菌组合物 |
-
2018
- 2018-06-26 CN CN201810667223.1A patent/CN110638842A/zh active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402464A (zh) * | 2020-12-14 | 2021-02-26 | 山东第一医科大学附属内分泌与代谢病医院 | 一种有益于2型糖尿病患者的复合益生菌组合物 |
| CN115137757A (zh) * | 2022-07-29 | 2022-10-04 | 承葛健康科技(广东)有限公司 | 一种辅助降血糖的益生菌组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2442814B1 (en) | Bifidobacteria for treating diabetes and related conditions | |
| CN110150669B (zh) | 一种适于糖尿病患者食用的益生菌组合物及其应用 | |
| EP2100604A1 (en) | Medium chain dicarboxylic acids and their derivates and metabolic disorders | |
| CN104855956A (zh) | 失眠医学配方食品 | |
| CN104187709A (zh) | 肥胖、减脂手术全营养配方食品 | |
| WO2018145664A1 (zh) | 提高耐力表现的抗疲劳组合物 | |
| CN106994134B (zh) | 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用 | |
| JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
| CN116004481B (zh) | 一种肠道菌株及其应用 | |
| CN104161263B (zh) | 儿童全营养配方食品 | |
| CN104187632A (zh) | 骨质疏松全营养配方食品 | |
| CN104256642A (zh) | 降三高壮阳全营养配方食品 | |
| CN104839678A (zh) | 肾病医学配方食品 | |
| WO2021103776A1 (zh) | 一种具有辅助防治儿童、青少年心理抑郁的作用的复合制剂 | |
| CN110638842A (zh) | 一种改善高血糖的益生菌组合物 | |
| CN104839655A (zh) | 降三高壮阳医学配方食品 | |
| CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
| CN113925169A (zh) | 一种缓解痛风益生菌组合物、其制备方法及其应用 | |
| CN104839679A (zh) | 心脏病医学配方食品 | |
| CN109527543A (zh) | 一种益生菌型低血糖生成指数匀浆膳 | |
| JP5971893B2 (ja) | ミネラル吸収改善剤 | |
| CN104839676A (zh) | 胃肠道吸收障碍医学配方食品 | |
| CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
| CN106666738A (zh) | 一种用于改善人体代谢紊乱状态的组合物及其制备方法 | |
| JP2015120646A (ja) | 創傷治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200103 |